These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 25076326)

  • 21. Detection of KRAS gene mutations in endoscopic ultrasound-guided fine-needle aspiration biopsy for improving pancreatic cancer diagnosis.
    Wang X; Gao J; Ren Y; Gu J; Du Y; Chen J; Jin Z; Zhan X; Li Z; Huang H; Lv S; Gong Y
    Am J Gastroenterol; 2011 Dec; 106(12):2104-11. PubMed ID: 21876563
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mutation of TP53 and alteration of p14(arf) expression in EGFR- and KRAS-mutated lung adenocarcinomas.
    Cortot AB; Younes M; Martel-Planche G; Guibert B; Isaac S; Souquet PJ; Commo F; Girard P; Fouret P; Brambilla E; Hainaut P; Soria JC
    Clin Lung Cancer; 2014 Mar; 15(2):124-30. PubMed ID: 24169260
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nicotine promotes initiation and progression of KRAS-induced pancreatic cancer via Gata6-dependent dedifferentiation of acinar cells in mice.
    Hermann PC; Sancho P; Cañamero M; Martinelli P; Madriles F; Michl P; Gress T; de Pascual R; Gandia L; Guerra C; Barbacid M; Wagner M; Vieira CR; Aicher A; Real FX; Sainz B; Heeschen C
    Gastroenterology; 2014 Nov; 147(5):1119-33.e4. PubMed ID: 25127677
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Does KRAS mutational status predict chemoresistance in advanced non-small cell lung cancer (NSCLC)?
    Macerelli M; Caramella C; Faivre L; Besse B; Planchard D; Polo V; Ngo Camus M; Celebic A; Koubi-Pick V; Lacroix L; Pignon JP; Soria JC
    Lung Cancer; 2014 Mar; 83(3):383-8. PubMed ID: 24439569
    [TBL] [Abstract][Full Text] [Related]  

  • 25. KRAS mutations in advanced nonsquamous non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy have no predictive value.
    Mellema WW; Dingemans AM; Thunnissen E; Snijders PJ; Derks J; Heideman DA; Van Suylen R; Smit EF
    J Thorac Oncol; 2013 Sep; 8(9):1190-5. PubMed ID: 23787801
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oncogenic KRAS signalling in pancreatic cancer.
    Eser S; Schnieke A; Schneider G; Saur D
    Br J Cancer; 2014 Aug; 111(5):817-22. PubMed ID: 24755884
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic significance of alterations in KRAS isoforms KRAS-4A/4B and KRAS mutations in colorectal carcinoma.
    Abubaker J; Bavi P; Al-Haqawi W; Sultana M; Al-Harbi S; Al-Sanea N; Abduljabbar A; Ashari LH; Alhomoud S; Al-Dayel F; Uddin S; Al-Kuraya KS
    J Pathol; 2009 Dec; 219(4):435-45. PubMed ID: 19824059
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Activated KrasG¹²D is associated with invasion and metastasis of pancreatic cancer cells through inhibition of E-cadherin.
    Rachagani S; Senapati S; Chakraborty S; Ponnusamy MP; Kumar S; Smith LM; Jain M; Batra SK
    Br J Cancer; 2011 Mar; 104(6):1038-48. PubMed ID: 21364589
    [TBL] [Abstract][Full Text] [Related]  

  • 29. KRAS mutation in patients with lung cancer: a predictor for poor prognosis but not for EGFR-TKIs or chemotherapy.
    Guan JL; Zhong WZ; An SJ; Yang JJ; Su J; Chen ZH; Yan HH; Chen ZY; Huang ZM; Zhang XC; Nie Q; Wu YL
    Ann Surg Oncol; 2013 Apr; 20(4):1381-8. PubMed ID: 23208128
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Endoscopic ultrasound-guided fine-needle aspiration biopsy coupled with KRAS mutation assay to distinguish pancreatic cancer from pseudotumoral chronic pancreatitis.
    Bournet B; Souque A; Senesse P; Assenat E; Barthet M; Lesavre N; Aubert A; O'Toole D; Hammel P; Levy P; Ruszniewski P; Bouisson M; Escourrou J; Cordelier P; Buscail L
    Endoscopy; 2009 Jun; 41(6):552-7. PubMed ID: 19533561
    [TBL] [Abstract][Full Text] [Related]  

  • 31. miRNA-96 suppresses KRAS and functions as a tumor suppressor gene in pancreatic cancer.
    Yu S; Lu Z; Liu C; Meng Y; Ma Y; Zhao W; Liu J; Yu J; Chen J
    Cancer Res; 2010 Jul; 70(14):6015-25. PubMed ID: 20610624
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).
    Cadranel J; Mauguen A; Faller M; Zalcman G; Buisine MP; Westeel V; Longchampt E; Wislez M; Coudert B; Daniel C; Chetaille B; Michiels S; Blons H; Solassol J; De Fraipont F; Foucher P; Urban T; Lacroix L; Poulot V; Quoix E; Antoine M; Danton G; Morin F; Chouaid C; Pignon JP
    J Thorac Oncol; 2012 Oct; 7(10):1490-502. PubMed ID: 22982650
    [TBL] [Abstract][Full Text] [Related]  

  • 33. EGFR and KRAS mutational analysis and their correlation to survival in pancreatic and periampullary cancer.
    Oliveira-Cunha M; Hadfield KD; Siriwardena AK; Newman W
    Pancreas; 2012 Apr; 41(3):428-34. PubMed ID: 22422135
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interferon/STAT1 and neuregulin signaling pathways are exploratory biomarkers of cetuximab (Erbitux®) efficacy in KRAS wild-type squamous carcinomas: a pathway-based analysis of whole human-genome microarray data from cetuximab-adapted tumor cell-line models.
    Oliveras-Ferraros C; Vazquez-Martin A; Queralt B; Adrados M; Ortiz R; Cufí S; Hernández-Yagüe X; Guardeño R; Báez L; Martin-Castillo B; Pérez-Martínez MC; Lopez-Bonet E; De Llorens R; Bernadó L; Brunet J; Menendez JA
    Int J Oncol; 2011 Dec; 39(6):1455-79. PubMed ID: 21833472
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Epidermal growth factor receptor expression and KRAS and BRAF mutations: study of 39 sinonasal intestinal-type adenocarcinomas.
    Projetti F; Durand K; Chaunavel A; Léobon S; Lacorre S; Caire F; Bessède JP; Moreau JJ; Coulibaly B; Labrousse F
    Hum Pathol; 2013 Oct; 44(10):2116-25. PubMed ID: 23791006
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mutated K-ras activates CDK8 to stimulate the epithelial-to-mesenchymal transition in pancreatic cancer in part via the Wnt/β-catenin signaling pathway.
    Xu W; Wang Z; Zhang W; Qian K; Li H; Kong D; Li Y; Tang Y
    Cancer Lett; 2015 Jan; 356(2 Pt B):613-27. PubMed ID: 25305448
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differential in vivo tumorigenicity of diverse KRAS mutations in vertebrate pancreas: A comprehensive survey.
    Park JT; Johnson N; Liu S; Levesque M; Wang YJ; Ho H; Huso D; Maitra A; Parsons MJ; Prescott JD; Leach SD
    Oncogene; 2015 May; 34(21):2801-6. PubMed ID: 25065594
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intratumor Heterogeneity of KRAS Mutation Status in Pancreatic Ductal Adenocarcinoma Is Associated With Smaller Lesions.
    Nagawkar SS; Abu-Funni S; Simon E; Bick T; Prinz E; Sabo E; Ben-Izhak O; Hershkovitz D
    Pancreas; 2016 Jul; 45(6):876-81. PubMed ID: 26646269
    [TBL] [Abstract][Full Text] [Related]  

  • 39. KRAS mutational subtype and copy number predict in vitro response of human pancreatic cancer cell lines to MEK inhibition.
    Hamidi H; Lu M; Chau K; Anderson L; Fejzo M; Ginther C; Linnartz R; Zubel A; Slamon DJ; Finn RS
    Br J Cancer; 2014 Oct; 111(9):1788-801. PubMed ID: 25167228
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacogenomics update in pancreatic cancer.
    Puri A; Saif MW
    JOP; 2014 Mar; 15(2):114-7. PubMed ID: 24618431
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.